Lowry Curley's guest appearances

Lowry Curley

Finding Genius Podcast

FutureTech Podcast

Laura Potterat

Marc Guell

Paul Turner

Jan Vijg

Eleftherios Mylonakis

Cory Kidd

Charles C.J

Helius Medical Technologies

Patrick McKeown

Michael G. Surette

Katelyn Parsons

John Tucker

Jake Kushner

Erik Gunther

Kim Kush

OwlTail

In this informative podcast, Lowry Curley, Chief Executive Officer at AxoSim, a biotech startup, talks about the ways his company is contributing to better drug development. Curley is a biotech entrepreneur with a background in biomedical engineering. His company’s innovative technology, Nerve-on-a-Chip™ is changing the way drugs are developed and tested.  Curley provides an overview of the past drug modeling that often ended with dismal results. He states that animal models are very ineffective at predicting whether drugs will be successful in human bodies, and surprisingly 94% of the time, after extensive animal testing, the drugs simply don’t work in humans. Curley is quick to point out that you really cannot equate animal biology to human biology. The biotech expert discusses how AxoSim creates models for drug testing. As Curley explains, they take skin cells and transform them back to stem cells and then ultimately differentiate that into a functional nerve cell. And as this is then engineered into a 3D environment, they can mimic complex interactions that a given cell could experience within the human body. Currently, AxoSim is working with many types of current drugs in development and also looking at past drugs that might have shown promise but were never released to the public for various issues, side effects, etc.  And Curley talks about the methods his company uses to seek out other companies doing similar work, to potentially partner with or acquire them, to maintain their mission of being the industry leader in new drug development processes. 

In this informative podcast, Lowry Curley, Chief Executive Officer at AxoSim, a biotech startup, talks about the ways his company is contributing to better drug development. Curley is a biotech entrepreneur with a background in biomedical engineering. His company’s innovative technology, Nerve-on-a-Chip™ is changing the way drugs are developed and tested.  Curley provides an overview of the past drug modeling that often ended with dismal results. He states that animal models are very ineffective at predicting whether drugs will be successful in human bodies, and surprisingly 94% of the time, after extensive animal testing, the drugs simply don’t work in humans. Curley is quick to point out that you really cannot equate animal biology to human biology. The biotech expert discusses how AxoSim creates models for drug testing. As Curley explains, they take skin cells and transform them back to stem cells and then ultimately differentiate that into a functional nerve cell. And as this is then engineered into a 3D environment, they can mimic complex interactions that a given cell could experience within the human body. Currently, AxoSim is working with many types of current drugs in development and also looking at past drugs that might have shown promise but were never released to the public for various issues, side effects, etc.  And Curley talks about the methods his company uses to seek out other companies doing similar work, to potentially partner with or acquire them, to maintain their mission of being the industry leader in new drug development processes.

Drug Design – Lowry Curley, CEO of AxoSim – Biotech Innovation That Is Changing the Pharmaceutical Industry 

Lowry Curley, Chief Executive Officer at AxoSim, a New Orleans based biotech startup, takes us on a thought-provoking journey through the major advances we are now seeing in drug development.   Curley is an entrepreneur with a keen interest in biotech. He has an extensive background in biomedical engineering and major experience in tissue engineering, product development, and drug development.    Curley’s biotech company seeks to leverage its unique Nerve-on-a-Chip™ technology to truly transform drug development. Curley discusses his company and how they are improving drug development. He states that animal models are actually terrible predictors for how drugs will work in humans, and drugs that are tested with animals end up failing for human use a shocking 94% of the time, after going through extensive testing. That’s a lot of work to end up with a drug that is essentially useless. Animal biology is simply not human biology, and Curley’s company’s method is changing the whole process and creating models that will work.    Curley explains how they create models for drug testing, talking about how they take skin cells and turn them back into stem cells and then differentiate that into a nerve cell. They then engineer this into a three-dimensional environment, to directly mimic the interactions that a cell would experience in a human body.    Curley talks about their funding, NIH, and others. He discusses some of the cancer drugs on the market that they are taking a look at, in order to improve or understand better their limitations. By using the AxoSim methods they are able to better grasp why drugs work and understand the side effects that they produce, which can help the pharmaceutical industry craft superior drugs with hopefully fewer side effects.    Curley says that his company is scouring academia and new companies for similar tech, and they are acquiring some new startups in order to bring everything together so AxoSim can be the industry leader.    AxoSim’s innovative platform technology seeks to advance the efficacy, and safety, of novel therapeutics, which they believe will also help manage costs and bring important new drugs to the market.

Lowry Curley, Chief Executive Officer at AxoSim, a New Orleans based biotech startup, takes us on a thought-provoking journey through the major advances we are now seeing in drug development. Curley is an entrepreneur with a keen interest in biotech. He has an extensive background in biomedical engineering and major experience in tissue engineering, product development, and drug development.  Curley’s biotech company seeks to leverage its unique Nerve-on-a-Chip™ technology to truly transform drug development. Curley discusses his company and how they are improving drug development. He states that animal models are actually terrible predictors for how drugs will work in humans, and drugs that are tested with animals end up failing for human use a shocking 94% of the time, after going through extensive testing. That’s a lot of work to end up with a drug that is essentially useless. Animal biology is simply not human biology, and Curley’s company’s method is changing the whole process and creating models that will work.  Curley explains how they create models for drug testing, talking about how they take skin cells and turn them back into stem cells and then differentiate that into a nerve cell. They then engineer this into a three-dimensional environment, to directly mimic the interactions that a cell would experience in a human body.  Curley talks about their funding, NIH, and others. He discusses some of the cancer drugs on the market that they are taking a look at, in order to improve or understand better their limitations. By using the AxoSim methods they are able to better grasp why drugs work and understand the side effects that they produce, which can help the pharmaceutical industry craft superior drugs with hopefully fewer side effects.  Curley says that his company is scouring academia and new companies for similar tech, and they are acquiring some new startups in order to bring everything together so AxoSim can be the industry leader.  AxoSim’s innovative platform technology seeks to advance the efficacy, and safety, of novel therapeutics, which they believe will also help manage costs and bring important new drugs to the market.

I Want a New Drug – Lowry Curley, Chief Executive Officer at AxoSim – The Amazing New Biotech Solutions That Are Literally Reinventing the Ways We Develop and Test Important Drugs